Chemoradiotherapy is currently the main treatment for locally advanced cervical cancer.
Nevertheless, the survival profile of locally advanced cervical cancer patients remains unsatisfactory because of metastasis and recurrence.
We aimed to assess the survival outcomes and safety of radiotherapy Â± chemotherapy combined with nimotuzumab (a human monoclonal antibody against epidermal growth factor receptor that has anti-tumor activities) for patients with locally advanced cervical cancer.
